Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Seaport Therapeutics, Inc. Common Stock
Market Cap
$929.83M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$934.79M
EBITDA Margin
-448.41%
TTM Avg
-402.69%
3Y Avg
-402.69%
5Y Avg
-402.69%
Market Cap
$923.53M
EBITDA Margin
-64.07%
TTM Avg
-61.50%
3Y Avg
-81.15%
5Y Avg
-81.15%
Market Cap
$921.06M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$914.73M
EBITDA Margin
20.95%
TTM Avg
21.20%
3Y Avg
20.44%
5Y Avg
19.67%
Market Cap
$952.91M
EBITDA Margin
-19083.66%
TTM Avg
-19083.66%
3Y Avg
-19083.66%
5Y Avg
-24221442.25%
Market Cap
$953.81M
EBITDA Margin
-1113.67%
TTM Avg
-2254.05%
3Y Avg
-2254.05%
5Y Avg
-2254.05%
Market Cap
$887.99M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Seaport Therapeutics, Inc. Common Stock (SPTX) | $929.83M | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $934.79M | -448.41% | -402.69% | -402.69% | -402.69% |
| CeriBell, Inc. (CBLL)vs › | $923.53M | -64.07% | -61.50% | -81.15% | -81.15% |
| MoonLake Immunotherapeutics (MLTX)vs › | $921.06M | N/A | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $914.73M | 20.95% | 21.20% | 20.44% | 19.67% |
| Savara Inc. (SVRA)vs › | $952.91M | -19083.66% | -19083.66% | -19083.66% | -24221442.25% |
| Aktis Oncology, Inc. (AKTS)vs › | $953.81M | -1113.67% | -2254.05% | -2254.05% | -2254.05% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $887.99M | N/A | N/A | N/A | N/A |
| Bioventus Inc. (BVS)vs › | $887.50M | 18.58% | 12.56% | -0.37% | 4.16% |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 17.12% | 8.95% | 16.20% | 17.02% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
